BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rivus Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Rivus Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07491458-236@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HU6: Phase 2 readout est. (NCT07491458)
DESCRIPTION:HU6\, phase 2\, MASH / NASH.\nStudy: A Trial to Investigate Saf
 ety\, Exposure\, and Efficacy of HU6 Compared With Placebo in Adult Partic
 ipants With Metabolic Dysfunction-associated Steatohepatitis (MASH)\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hu6#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07491458
URL:https://assetmemo.bio/drug/hu6#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
